Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open in red
Tue, 23 Aug 09:30 am

Asian stock markets have opened the day on a firm note. Stock markets in South Korea (up 2.5%), China (up 0.9%) and Hong Kong (up 0.4%), are leading the gains. The Indian stock markets have opened the day on a weak note. Banking and Auto stocks are trading weak. However, stocks in the IT and Consumer Goods space are in the green.

The BSE-Sensex is trading lower by around 55 points (0.3%) and the NSE-Nifty is down by around 8 points (0.1%). However, Midcap and small cap stocks are trading in the green, with the BSE Midcap and BSE Small cap indices up by 0.2% and 0.3% respectively. The rupee is trading at 45.75 to the US dollar.

Pharma stocks have opened the day on a firm note with Aurobindo Pharma and Sun Pharma leading the gains. However Biocon is in the red. Biopharma major, Biocon's subsidiary Clinigene International has entered into a joint venture with Spaulding Clinical Research of the US. The partnership will focus in providing comprehensive early clinical solutions to pharmaceutical and biotech clients. The Chief Operating Officer of Clinigene said that the partnership establishes a reliable, trustworthy and cost-efficient global footprint for clinical pharma services. It also provides an opportunity for both companies to engage pharma clients strategically and accelerate first-in-human to proof-of-concept clinical development. The US based company has an expertise in the domain of clinical pharmacology, cardiac core lab and medical device manufacturing. The company also operates a unit having 105 beds in West Bend, Wisconsin (US).

Steel stocks have opened the day on a weak note with Tata Steel and SAIL leading the losses. A steel ministry official admitted that SAIL is planning to make a fresh equity issue to raise money for its on-going modernization and expansion plans. The officials are in the process to file the prospectus with the SEBI by the end of September. The Government expects the stock market valuations to improve towards the end of the year and it wants to be ready for the same. It is said that the Government should be able to raise a significant amount through the sale of part of its stake in SAIL. The government is also planning to sell stake in two other companies -National Aluminium Co Ltd (Nalco) and Hindustan Copper without follow-on offers (FPO). In all the government is planning to garner more than Rs 80 bn. Last year, SAIL had planned a two-tranche FPO of 5% each but could not get it done.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.